Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alexandra Foettinger-Vacha"'
Autor:
Samuele Zoratto, Victor U. Weiss, Gernot Friedbacher, Carsten Buengener, Robert Pletzenauer, Alexandra Foettinger-Vacha, Michael Graninger, Guenter Allmaier
Publikováno v:
ACS Omega, Vol 6, Iss 25, Pp 16428-16437 (2021)
Externí odkaz:
https://doaj.org/article/109ea629399c42f19723f6784b8c6d2e
Autor:
Alexandra Foettinger-Vacha, Victor U. Weiss, Carsten Buengener, Samuele Zoratto, Guenter Allmaier, Gernot Friedbacher, Michael Graninger, Robert Pletzenauer
Publikováno v:
ACS Omega
ACS Omega, Vol 6, Iss 25, Pp 16428-16437 (2021)
ACS Omega, Vol 6, Iss 25, Pp 16428-16437 (2021)
Adeno-associated virus (AAV)-based virus-like particles (VLPs) are thriving vectors of choice in the biopharmaceutical field of gene therapy. Here, a method to investigate purified AAV serotype 8 (AAV8) batches via a nanoelectrospray gas-phase mobili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0e2331d0b052bc736c83ad73f1165c7
https://pubmed.ncbi.nlm.nih.gov/34235314
https://pubmed.ncbi.nlm.nih.gov/34235314
Autor:
Alexandra Foettinger-Vacha, Martin Kaliwoda, Peter Matthiessen, Meinhard Hasslacher, Hanspeter Rottensteiner, Peter L Turecek, Artur Mitterer, Friedrich Scheiflinger
Publikováno v:
Blood. 120:2236-2236
Abstract 2236 Baxter has developed a human recombinant (r) ADAMTS13 for treatment of patients with hereditary TTP. The protein is produced in a CHO cell-line using serum and protein-free fermentation technology. The purification process does not use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eca83c3317327a30140dd70e81e3d3d
https://doi.org/10.1182/blood.v120.21.2236.2236
https://doi.org/10.1182/blood.v120.21.2236.2236
Autor:
Friedrich Scheiflinger, Peter Matthiessen, Martin Kaliwoda, Meinhard Hasslacher, Alexandra Foettinger-Vacha, Peter Turecek, Artur Mitterer, Hanspeter Rottensteiner
Publikováno v:
Blood. 120:2235-2235
Abstract 2235 Baxter has developed a human recombinant (r) ADAMTS13 for treatment of patients with hereditary TTP. Here we characterize preclinical and clinical lots of rADAMTS13 with respect to their functional properties. The ability of rADAMTS13 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eed54f31f760bd45a9e36704e24d79d
https://doi.org/10.1182/blood.v120.21.2235.2235
https://doi.org/10.1182/blood.v120.21.2235.2235